Dr. Jie’er Ying: Exploring New Pathways for Integrative Rehabilitation in Gastric Cancer to Improve Patient Outcomes

Dr. Jie’er Ying: Exploring New Pathways for Integrative Rehabilitation in Gastric Cancer to Improve Patient Outcomes

The 2024 CACA Integrative Gastric Cancer Conference took place in Wuhan from October 18-19, 2024. Oncology Frontier invited Dr. Jie’er Ying, Chairman of the Chinese Anti-Cancer Association’s Gastric Cancer Integrative Rehabilitation Committee and Head of the Hepatobiliary and Gastric Oncology Department at Zhejiang Cancer Hospital, to discuss the current state and development of integrative rehabilitation for gastric cancer.
ESMO 2024丨Dr. Dingwei Ye: Exciting Advances with EGFR/HER3 Dual-Antibody ADC, New Successes in Urologic Oncology

ESMO 2024丨Dr. Dingwei Ye: Exciting Advances with EGFR/HER3 Dual-Antibody ADC, New Successes in Urologic Oncology

The 2024 European Society for Medical Oncology (ESMO) Congress was held from September 13 to 17 in Barcelona, Spain. During the event, multiple key studies in urologic oncology were highlighted. Dr. Dingwei Ye from Fudan University Shanghai Cancer Center presented preliminary findings on the safety, tolerability, and efficacy of BL-B01D1, a novel EGFR/HER3 dual-targeting antibody-drug conjugate (ADC), in patients with previously treated metastatic urothelial carcinoma (UC), garnering considerable attention. Urology Frontier invited Dr. Dingwei Ye to share major developments in urologic oncology from the congress, discuss new dual-targeted therapies for advanced UC, and highlight the Fudan University Shanghai Cancer Center’s progress in this area.
ILCA 2024丨Dr. Yunfei Yuan: REFINE Study Reports Subgroup Data for Interventional Therapy

ILCA 2024丨Dr. Yunfei Yuan: REFINE Study Reports Subgroup Data for Interventional Therapy

The 18th International Liver Cancer Association (ILCA) Annual Conference took place in Toronto, Canada, from October 17-19, 2024. During the conference, Prof. Richard S. Finn of the David Geffen School of Medicine at UCLA presented subgroup data from the real-world REFINE study, highlighting that patients with unresectable hepatocellular carcinoma (uHCC) who received transarterial chemoembolization (TACE) or transarterial radioembolization (TARE) in addition to regorafenib had better survival trends. Oncology Frontier invited Dr. Yunfei Yuan from the Sun Yat-sen University Cancer Center to discuss and provide insights on this study.
Dr. Wenyu Shi on Challenges and Strategies for Treating Elderly Patients with DLBCL

Dr. Wenyu Shi on Challenges and Strategies for Treating Elderly Patients with DLBCL

From October 18 to 20, 2024, the “2024 Jiangsu Provincial Association of Hematology Physicians Annual Meeting,” hosted by the Jiangsu Provincial Association of Hematology Physicians and organized by Taizhou People's Hospital and the First Affiliated Hospital of Nanjing Medical University, took place in Taizhou, Jiangsu. This event focused on standardized diagnosis and treatment of hematological diseases, providing a high-level academic exchange platform for professionals in hematology. We invited Dr. Wenyu Shi, the executive chairman from Affiliated Hospital of Nantong University, to share his insights with Hematology Frontier.
AMN 2024| Prof. Wenming Chen Receives AMN Distinguished Achievement Award, Leading China’s Advances in Multiple Myeloma

AMN 2024| Prof. Wenming Chen Receives AMN Distinguished Achievement Award, Leading China’s Advances in Multiple Myeloma

On October 19, 2024, the 8th Asian Myeloma Network (AMN) Summit was held in Seoul, South Korea. At this event, the International Myeloma Foundation (IMF) hosted the AMN Awards Ceremony. Prof. Wenming Chen from Beijing Chaoyang Hospital, Capital Medical University, received the AMN Distinguished Achievement Award, recognizing his significant contributions to the field of multiple myeloma (MM) and China’s progress in this field. Following the ceremony, Hematology Frontier had the privilege of interviewing Professor Chen. He shared his thoughts on this award, the development of the AMN, and his insights and outlook on the current and future treatment landscape for MM.
IHPBA President Interview | Professor Eduard Jonas: The Transformation of Personalized Hepatocellular Carcinoma Treatment from a Global Perspective

IHPBA President Interview | Professor Eduard Jonas: The Transformation of Personalized Hepatocellular Carcinoma Treatment from a Global Perspective

From October 25 to 27, 2024, the 9th Academic Symposium of the International Hepato-Pancreato-Biliary Association China Conference was held in Wuhan. The conference attracted more than 50 internationally renowned experts and scholars from over 20 countries including the United States, Germany, France, Russia, and Australia, as well as 21 academicians from the two academies and over 700 domestic experts in the field of hepato-pancreato-biliary. At this conference, Professor Eduard Jonas from the Groote Schuur Hospital, University of Cape Town, and President of the Europe-Africa Hepato-Pancreato-Biliary Association (E-AHPBA), delivered a wonderful report titled "Transitioning from guidelines to personalized medicine in the treatment of hepatocellular carcinoma - a global perspective." we invited Professor Eduard Jonas for an in-depth interview to share fascinating insights on the personalized treatment of liver cancer with colleagues in the field.
ASH 2024 | Prof. Xiaohui Zhang’s Team Presents 11 Groundbreaking Studies with 3 Oral Presentations！

ASH 2024 | Prof. Xiaohui Zhang’s Team Presents 11 Groundbreaking Studies with 3 Oral Presentations！

The 66th American Society of Hematology (ASH) Annual Meeting will be held from December 7-10, 2024, in San Diego, USA. As the world’s largest and most comprehensive international academic conference in hematology, ASH attracts thousands of experts and scholars from around the globe each year, who come to share cutting-edge developments and breakthrough clinical data. At this year’s conference, Prof. Xiaohui Zhang’s team from the Department of Hematology, Peking University People’s Hospital, and the Institute of Hematology, Peking University, will showcase an impressive total of 11 studies, including three selected for oral presentations, underscoring China’s outstanding achievements in hematology research. This preview highlights these three oral presentations, inviting readers to follow the presentation schedules and learn more about the fascinating details and stories behind these impactful studies.
Overview of Key Updates in the 2024 NCCN Guidelines for Acute Myeloid Leukemia (AML) – First Edition

Overview of Key Updates in the 2024 NCCN Guidelines for Acute Myeloid Leukemia (AML) – First Edition

The latest 2024 NCCN guidelines for Acute Myeloid Leukemia (AML) have been published, presenting significant revisions compared to the 2023, Version 6 update. The new edition brings substantial updates in areas such as intensive induction therapy for AML, post-induction follow-up and reinduction therapy, consolidation, and maintenance treatments.
IHPBA President Interview | Professor René Adam: Exploring Innovative Treatments for CRLM

IHPBA President Interview | Professor René Adam: Exploring Innovative Treatments for CRLM

October 21-27, 2024, Wuhan, at the 9th Academic Symposium of the Chinese Chapter of the International Hepato-Pancreato-Biliary Association (IHPBA), we interviewed Professor René Adam, the current President of the IHPBA and a famous surgeon at AP-HP Paul Brousse Hospital in Paris, France, to share his research explorations on the use of liver transplantation combined with chemotherapy for the treatment of colorectal cancer with liver metastases (CRLM).